← back to search

Michael Michaelides

National Institutes of Health · US
Area of research
Cellular and Molecular Neuroscience · Molecular Biology
Research interest
Research interests include Neurotransmitter Receptor Influence on Behavior, Neuroscience and Neuropharmacology Research, Receptor Mechanisms and Signaling, and Regulation of Appetite and Obesity.
h-index
37
citations
6,135
works
161
NIH funding
primary concept
email

Recent publications

Cocaine chemogenetics blunts drug-seeking by synthetic physiology
Nature 2025cited by 1position: middledoi
Sex dependence of opioid-mediated responses to subanesthetic ketamine in rats
Nature Communications 2024cited by 32position: middledoi
In vivo photopharmacology with light-activated opioid drugs
Neuron 2023cited by 37position: middledoi
Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone
Molecular Psychiatry 2023cited by 26position: lastdoi
The SARS-CoV-2 spike protein binds and modulates estrogen receptors
Science Advances 2022cited by 49position: lastdoi
Chemogenetics: DREADDs
2022cited by 3position: firstdoi
Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Molecular Psychiatry 2021cited by 259position: lastdoi
Mechanisms of ketamine and its metabolites as antidepressants
Biochemical Pharmacology 2021cited by 161position: middledoi
High-potency ligands for DREADD imaging and activation in rodents and monkeys
Nature Communications 2019cited by 216position: lastdoi
Ultrapotent chemogenetics for research and potential clinical applications
Science 2019cited by 197position: middledoi
Ultrastructural localization of <scp>DREADD</scp> s in monkeys
European Journal of Neuroscience 2019cited by 48position: middledoi
Chemogenetics revealed: DREADD occupancy and activation via converted clozapine
Science 2017cited by 1,024position: lastdoi
Dopamine D2 Receptor Signaling in the Nucleus Accumbens Comprises a Metabolic–Cognitive Brain Interface Regulating Metabolic Components of Glucose Reinforcement
Neuropsychopharmacology 2017cited by 16position: firstdoi
Acute engagement of Gq-mediated signaling in the bed nucleus of the stria terminalis induces anxiety-like behavior
Molecular Psychiatry 2016cited by 95position: middledoi
Chemogenetics: DREADDs
2016cited by 4position: firstdoi
Elucidation of The Behavioral Program and Neuronal Network Encoded by Dorsal Raphe Serotonergic Neurons
Neuropsychopharmacology 2015cited by 166position: middledoi
Chemogenetics: DREADDs
2015cited by 0position: firstdoi
DREAMM: A Biobehavioral Imaging Methodology for Dynamic In Vivo Whole-Brain Mapping of Cell Type-Specific Functional Networks
Neuropsychopharmacology 2014cited by 23position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Jordi Bonaventura · Johns Hopkins Medicine7 papers (2017–2025)Juan L. Gomez · Johns Hopkins Medicine7 papers (2017–2025)Yasmin L. Hurd · Mount Sinai Hospital6 papers (2014–2022)Marjorie R. Levinstein · Columbia University4 papers (2023–2025)Reece C. Budinich · Johns Hopkins Medicine3 papers (2023–2025) · 3 papers (2023–2025) · 3 papers (2019–2025) · 2 papers (2017–2019)Xing Hu · Emory University2 papers (2019–2019)Óscar Solís · University of York2 papers (2021–2025)Scott M. Sternson · Howard Hughes Medical Institute2 papers (2019–2025)Christopher Magnus · Howard Hughes Medical Institute2 papers (2019–2025)Antonello Bonci · National Institute on Drug Abuse2 papers (2017–2019)Matthew A. Boehm · Brown University2 papers (2019–2021)Martin G. Pomper · Institute for Advanced Journalism Studies2 papers (2017–2019)Marta Sánchez‐Soto · McGill University Health Centre2 papers (2019–2021)Adriana Galván · Emory University2 papers (2019–2019) · 2 papers (2021–2025)Thomas L. Kash · University of North Carolina at Chapel Hill2 papers (2015–2016)David R. Sibley · National Institutes of Health2 papers (2019–2021)